BXPHF
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | -0.02 | $16M | -$33M |
| 2025 Q4 | -0.03 | $5M | -$48M |
| 2024 Q2 | -0.02 | $377,597 | -$31M |
| 2024 Q4 | -0.01 | $2M | -$4M |
| 2023 Q2 | -0.00 | $377,930 | -$19M |
| 2023 Q4 | -0.00 | $526,976 | -$8M |
| 2022 Q2 | -0.00 | $387,997 | -$11M |
| 2022 Q4 | -0.01 | $1M | -$9M |